BioSpace News Archive

Westlake Village BioPartners announced the launch of its third fund of $450 million to incubate and grow early stage next-generation biotechnology companies in the Los Angeles region and beyond.

LianBio announced data from the Phase 3 EXPLORER-CN trial of mavacamten in Chinese symptomatic obstructive hypertrophic cardiomyopathy patients were accepted for a late-breaking presentation at the European Society of Cardiology Congress 2023 taking place August 25-28, 2023 in Amsterdam, Netherlands.

Ondine Biomedical was awarded the TAYYABA HASAN IMPACT AWARD at the 18th World Congress of International Photodynamic Association in Tampere, Finland for demonstrating exceptional perseverance and clinical acumen.

The Barbara Ann Karmanos Cancer Institute welcomes Arnold D’Ambrosio as the new Chief Development Officer, effective Monday, July 10, 2023.

Bio-Path Holdings, Inc. announced completion of the first dose cohort of the dose escalation portion of its Phase 1/1b clinical trial of BP1001-A in patients with solid tumors, including ovarian, endometrial, pancreatic and breast cancer.

AccuStem Sciences, Inc. and EmeritusDX announced the execution of an agreement wherein both companies will jointly manage scientific operations and R&D for AccuStem’s product portfolio.

Virios Therapeutics, Inc. today announced that female patients diagnosed with Long-COVID illness, otherwise known as Post-Acute Sequelae of COVID-19 infection (“PASC”), exhibited clinically and statistically significant improvements in fatigue, pain, and symptoms of autonomic dysfunction and general well-being related to Long-COVID.

Acumen Pharmaceuticals, Inc. will hold a conference call today to discuss the positive topline results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage AβO targeting antibody therapy in early AD.

Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced additional positive initial data from its ongoing Phase 1 healthy volunteer clinical trial of its lead investigational monoclonal antibody (mAb) candidate, VYD222.

BioVie Inc. announced data from a poster detailing the epigenetic basis for how in a Phase 2 exploratory biomarker study its drug candidate NE3107 may have potentially regulated specific genes in a manner significantly correlated with observed cognitive and biomarker improvements.